{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2014_0155330_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"018-553-791-272-743","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11681,"type":"PATENT","title":"Weizmann Institute of Science - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8051,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8337,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:weizma* inst*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 8079
Search Applicants and Owners separately:weizma* inst*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 8079
exposing a cell expressing Atg12 and a Bcl-2 anti-apoptotic protein to a putative pro-apoptotic agent; and\n
determining the binding of Atg12 to the Bcl-2 anti-apoptotic protein;\nwherein enhancement of said binding indicates that the agent is a pro-apoptotic agent."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, further comprising the step of:\n
determining the change in survival of the cell in the presence of the agent relative to a control."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the Bcl-2 anti-apoptotic protein is selected from the group consisting of: Bcl-2, Bcl-XL, Bcl-w, Bcl-B, Mcl-1 and A1 (Bfl-1) and wherein the putative agent is selected from the group consisting of: peptides, nucleic acids, organic molecules, inorganic compounds and antibodies or antigen binding fragments thereof."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["A pro-apoptotic agent obtained by the method according to claim 18."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["A method of screening for an anti-apoptotic agent, the method comprising the steps of:\n
exposing a cell expressing Atg12 and a Bcl-2 anti-apoptotic protein to a putative anti-apoptotic agent; and\n
determining the binding of Atg12 to the Bcl-2 anti-apoptotic protein;\n
wherein reduction of said binding indicates that the agent is an anti-apoptotic agent."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 22 further comprising:\n
determining the change in survival of the cell in the presence of the agent relative to a control, or wherein the putative agent is selected from the group consisting of: peptides, nucleic acids, organic molecules, inorganic compounds and antibodies or antigen binding fragments thereof."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["An anti-apoptotic agent obtained by the method according to claim 22 or a pharmaceutical composition comprising said anti-apoptotic agent as an active ingredient, and a pharmaceutically acceptable carrier."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating a disease or disorder characterized by excessive cellular death in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the anti-apoptotic agent of claim 24."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 25, wherein the disease or disorder characterized by excessive cellular death is a neurodegenerative disease or wherein the disease or disorder is associated with neuronal cell death."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 26, wherein the disease or disorder is a neurodegenerative disease selected from the group consisting of: Alzheimer's disease, Huntington's disease, Parkinson's disease, neurodegeneration due to stroke, amyotrophic lateral sclerosis (ALS), Pick's disease, Progressive Supranuclear Palsy (PSP), fronto-temporal dementia (FTD), pallido-ponto-nigral degeneration (PPND), Guam-ALS syndrome, pallido-nigro-luysian degeneration (PNLD) and cortico-basal degeneration (CBD), or wherein the disease or disorder is associated with neuronal cell death and is selected form the group consisting of: epilepsy, hypoxia/ischemia related acute brain injury, Parkinson's disease and Alzheimer's disease."],"number":27,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}